BRASH Syndrome Unmasked: Digoxin Toxicity in the Setting of Cardiogenic Shock and Multiorgan Dysfunction
Case Reports in Critical Care · 2026-01 · 2026 (1)
DOI: 10.1155/crcc/8778210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Case Reports in Critical Care, online erschienen am 15.07.2026. Verfasst von Spencer Boehm und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Corewell Health Lakeland, Saint Joseph, Michigan, USA. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Digoxin, a cardiac glycoside historically used for rate control in atrial arrhythmias and symptom relief in chronic heart failure, possesses a narrow therapeutic index and is highly susceptible to pharmacokinetic and pharmacodynamic disruption in critically ill patients. Its use in acute decompensated heart failure and cardiogenic shock is therefore controversial. We present the case of a 75‐year‐old woman with chronic heart failure with reduced ejection fraction who developed progressive bradycardia and cardiogenic shock after treatment with digoxin and amiodarone for 2:1 atrial flutter. Her hospital course was complicated by acute kidney injury, severe hyperkalemia, ischemic hepatitis, and persistent bradycardia following electrical cardioversion. Serum digoxin levels were supratherapeutic early in the intensive care unit course and subsequently normalized, though bradyarrhythmias persisted. The patient′s presentation and clinical trajectory were consistent with BRASH (bradycardia, renal failure, AV‐nodal blockade, shock, and hyperkalemia) syndrome , with amiodarone–digoxin interaction and systemic hypoperfusion likely amplifying myocardial digoxin sensitivity. She improved with supportive therapy, correction of metabolic derangements, withdrawal of AV‐nodal‐blocking agents, and cardioversion, without administration of digoxin‐specific antibody fragments. This case highlights the importance of early recognition of BRASH physiology, cautious use of AV‐nodal blockers in low‐output states, and prioritization of underlying physiologic correction over reliance on serum drug levels alone in critically ill patients.
Autor:innen und Institutionen
- Department of Internal Medicine, Corewell Health Lakeland, Saint Joseph, Michigan, USA.
- Department of Pharmacy, Corewell Health Lakeland, Saint Joseph, Michigan, USA.
ORCID-Profile: Spencer Boehm
Zitieren
APA
Boehm, S., & Bruni, J. (2026). BRASH Syndrome Unmasked: Digoxin Toxicity in the Setting of Cardiogenic Shock and Multiorgan Dysfunction. Case Reports in Critical Care, 2026(1). https://doi.org/10.1155/crcc/8778210
Vancouver
Boehm S, Bruni J. BRASH Syndrome Unmasked: Digoxin Toxicity in the Setting of Cardiogenic Shock and Multiorgan Dysfunction. Case Reports in Critical Care. 2026;2026(1). doi:10.1155/crcc/8778210
BibTeX
@article{Boehm2026,
author = {Boehm, Spencer and Bruni, Jordan},
title = {BRASH Syndrome Unmasked: Digoxin Toxicity in the Setting of Cardiogenic Shock and Multiorgan Dysfunction},
journal = {Case Reports in Critical Care},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crcc/8778210}
}
EUVIMED